Chinese General Practice ›› 2021, Vol. 24 ›› Issue (21): 2640-2645.DOI: 10.12114/j.issn.1007-9572.2021.00.546
• Monographic Research • Previous Articles Next Articles
Published:
2021-07-20
Online:
2021-07-20
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2021.00.546
[1]GWEE K A,GONLACHANVIT S,GHOSHAL U C,et al.Second Asian consensus on irritable bowel syndrome[J].J Neurogastroenterol Motil,2019,25(3):343-362.DOI:10.5056/jnm19041. [2]CHEY W D,KURLANDER J,ESWARAN S.Irritable bowel syndrome:a clinical review[J].JAMA,2015,313(9):949-958.DOI:10.1001/jama.2015.0954. [3]SPERBER A D,DUMITRASCU D,FUKUDO S,et al.The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies:a Rome Foundation working team literature review[J].Gut,2017,66(6):1075-1082.DOI:10.1136/gutjnl-2015-311240. [4]吴寒,张振玉.肠易激综合征东西方指南对比解读[J].胃肠病学和肝病学杂志,2019,28(9):961-967. WU H,ZHANG Z Y.An interpretation of the eastern and western guidelines for irritable bowel syndrome[J].Chinese Journal of Gastroenterology and Hepatology,2019,28(9):961-967. [5]H?USER W,MARSCHALL U,LAYER P,et al.The prevalence,comorbidity,management and costs of irritable bowel syndrome[J].Dtsch Arztebl Int,2019,116(27/28):463-470.DOI:10.3238/arztebl.2019.0463. [6]VU J,KUSHNIR V,CASSELL B,et al.The impact of psychiatric and extraintestinal comorbidity on quality of life and bowel symptom burden in functional GI disorders [J].Neurogastroenterol Motil,2014,26(9):1323-1332.DOI:10.1111/nmo.12396. [7]徐心田,徐丹华,陆为民.神经-内分泌-免疫系统调控异常与肠易激综合征相关性的研究进展 [J].中国全科医学,2020,23(26):3369-3374.DOI:10.12114/j.issn.1007-9572.2019.00.727. XU X T,XU D H,LU W M.Relationship between irritable bowel syndrome and regulatory abnormalities of neuroendocrine-immune network [J].Chinese General Practice,2020,23(26):3369-3374.DOI:10.12114/j.issn.1007-9572.2019.00.727. [8]SIMRéN M,T?RNBLOM H,PALSSON O S,et al.Management of the multiple symptoms of irritable bowel syndrome[J].Lancet Gastroenterol Hepatol,2017,2(2):112-122.DOI:10.1016/s2468-1253(16)30116-9. [9]何力,杨力,凌志维,等.基于脑肠交互机制探讨肠道微生物调节IBS-D内脏高敏的研究进展 [J].中国实验方剂学杂志,2019,25(11):224-229. HE L,YANG L,LING Z W,et al.Effect of intestinal microbiota in regulating visceral hypersensitivity of IBS-D based on brain-gut interacting mechanism [J].Chinese Journal of Experimental Traditional Medical Formulae,2019,25(11):224-229. [10]刘涛,刘霞,张驰,等.基于脑-肠-菌轴阐述针刺与肠易激综合征的关系 [J].中国中医药现代远程教育,2018,16(8):152-155. LIU T,LIU X,ZHANG C,et al.Discussion on the relationship between acupuncture and irritable bowel syndrome based on the brain-gut-microbiota axis [J].Chinese Medicine Modern Distance Education of China,2018,16(8):152-155. [11]NG Q X,SOH A Y S,LOKE W,et al.The role of inflammation in irritable bowel syndrome (IBS)[J].J Inflamm Res,2018,11:345-349.DOI:10.2147/JIR.S174982. [12]朱诗玮,王志仁,段丽萍.中国肠易激综合征和抑郁症患者具有相同的遗传易感性位点 [J].中华内科杂志,2020,59(5):391. ZHU S W,WANG Z R,DUAN L P.Shared genetic susceptibilities for irritable bowel syndrome and depressive disorder in Chinese patients [J].Chinese Journal of Internal Medicine,2020,59(5):391. [13]SIBELLI A,MOSS-MORRIS R,CHALDER T,et al.Patients' perspectives on GP interactions after cognitive behavioural therapy for refractory IBS:a qualitative study in UK primary and secondary care[J].Br J Gen Pract,2018,68(674):e654-662.DOI:10.3399/bjgp18x698321. [14]DUAN T Y,CIL O,TSE C M,et al.Inhibition of CFTR-mediated intestinal chloride secretion as potential therapy for bile acid diarrhea[J].Faseb J,2019,33(10):10924-10934.DOI:10.1096/fj.201901166R. [15]KUA C H,NG S T,LHODE R,et al.Irritable bowel syndrome and other gastrointestinal disorders:evaluating self-medication in an Asian community setting[J].Int J Clin Pharm,2012,34(4):561-568.DOI:10.1007/s11096-012-9644-0. [16]CREED F.Review article:the incidence and risk factors for irritable bowel syndrome in population-based studies[J].Aliment Pharmacol Ther,2019,50(5):507-516.DOI:10.1111/apt.15396. [17]KLEM F,WADHWA A,PROKOP L J,et al.Prevalence,risk factors,and outcomes of irritable bowel syndrome after infectious enteritis:a systematic review and meta-analysis[J].Gastroenterology,2017,152(5):1042-1054.e1.DOI:10.1053/j.gastro.2016.12.039. [18]LACKNER J M,QUIGLEY B M,RADZIWON C D,et al.IBS patients' treatment expectancy and motivation impacts quality of the therapeutic alliance with provider:results of the IBS outcome study[J].J Clin Gastroenterol,2021,55(5):411-421.DOI:10.1097/mcg.0000000000001343. [19]EVERITT H A,LANDAU S,O'REILLY G,et al.Assessing telephone-delivered cognitive-behavioural therapy (CBT) and web-delivered CBT versus treatment as usual in irritable bowel syndrome (ACTIB):a multicentre randomised trial[J].Gut,2019,68(9):1613-1623.DOI:10.1136/gutjnl-2018-317805. [20]HOLVOET T,JOOSSENS M,VáZQUEZ-CASTELLANOS J F,et al.Fecal microbiota transplantation reduces symptoms in some patients with irritable bowel syndrome with predominant abdominal bloating:short-and long-term results from a placebo-controlled randomized trial[J].Gastroenterology,2021,160(1):145-157.e8.DOI:10.1053/j.gastro.2020.07.013. [21]WINDGASSEN S,MOSS-MORRIS R,EVERITT H,et al.Cognitive and behavioral differences between subtypes in refractory irritable bowel syndrome[J].Behav Ther,2019,50(3):594-607.DOI:10.1016/j.beth.2018.09.006. [22]LACKNER J M,JACCARD J,KEEFER L,et al.Improvement in gastrointestinal symptoms after cognitive behavior therapy for refractory irritable bowel syndrome[J].Gastroenterology,2018,155(1):47-57.DOI:10.1053/j.gastro.2018.03.063. [23]LACKNER J M,JACCARD J,RADZIWON C D,et al.Durability and decay of treatment benefit of cognitive behavioral therapy for irritable bowel syndrome:12-month follow-up[J].Am J Gastroenterol,2019,114(2):330-338.DOI:10.1038/s41395-018-0396-x. [24]KAWANISHI H,SEKIGUCHI A,FUNABA M,et al.Cognitive behavioral therapy with interoceptive exposure and complementary video materials for irritable bowel syndrome (IBS):protocol for a multicenter randomized controlled trial in Japan[J].Biopsychosoc Med,2019,13:14.DOI:10.1186/s13030-019-0155-2. [25]HUANG H L,CHEN H T,LUO Q L,et al.Relief of irritable bowel syndrome by fecal microbiota transplantation is associated with changes in diversity and composition of the gut microbiota[J].J Dig Dis,2019,20(8):401-408.DOI:10.1111/1751-2980.12756. [26]CRUZ-AGULIAR R M,WANTIA N,CLAVEL T,et al.An open-labeled study on fecal microbiota transfer in irritable bowel syndrome patients reveals improvement in abdominal pain associated with the relative abundance of Akkermansia muciniphila[J].Digestion,2019,100(2):127-138.DOI:10.1159/000494252. [27]KROUWEL M,JOLLY K,GREENFIELD S.How do people with refractory irritable bowel syndrome perceive hypnotherapy?:Qualitative study[J].Complement Ther Med,2019,45:65-70.DOI:10.1016/j.ctim.2019.05.020. [28]FORD A C,LACY B E,TALLEY N J.Irritable bowel syndrome [J].N Engl J Med,2017,376(26):2566-2578. [29]BLACK C J,THAKUR E R,HOUGHTON L A,et al.Efficacy of psychological therapies for irritable bowel syndrome:systematic review and network meta-analysis[J].Gut,2020,69(8):1441-1451.DOI:10.1136/gutjnl-2020-321191. [30]HARVEY R F,HINTON R A,GUNARY R M,et al.Individual and group hypnotherapy in treatment of refractory irritable bowel syndrome[J].Lancet,1989,1(8635):424-425.DOI:10.1016/s0140-6736(89)90013-5. [31]FORD A C,LACY B E,HARRIS L A,et al.Effect of antidepressants and psychological therapies in irritable bowel syndrome:an updated systematic review and meta-analysis[J].Am J Gastroenterol,2019,114(1):21-39.DOI:10.1038/s41395-018-0222-5. [32]QUIGLEY E M,FRIED M,GWEE K A,et al.World gastroenterology organisation global guidelines irritable bowel syndrome:a global perspective update September 2015[J].J Clin Gastroenterol,2016,50(9):704-713.DOI:10.1097/mcg.0000000000000653. [33]HOOKWAY C,BUCKNER S,CROSLAND P,et al.Irritable bowel syndrome in adults in primary care:summary of updated NICE guidance[J].BMJ,2015,350:h701.DOI:10.1136/bmj.h701. [34]BECK A T.Thinking and depression:Ⅱ.theory and therapy[J].Arch Gen Psychiatry,1964,10(6):561-571. [35]LACKNER J M.Skills over pills? A clinical gastroenterologist's primer in cognitive behavioral therapy for irritable bowel syndrome[J].Expert Rev Gastroenterol Hepatol,2020,14(7):601-618.DOI:10.1080/17474124.2020.1780118. [36]EVERITT H A,LANDAU S,O'REILLY G,et al.Cognitive behavioural therapy for irritable bowel syndrome:24-month follow-up of participants in the ACTIB randomised trial[J].Lancet Gastroenterol Hepatol,2019,4(11):863-872.DOI:10.1016/s2468-1253(19)30243-2. [37]EVERITT H,LANDAU S,LITTLE P,et al.Therapist telephone-delivered CBT and web-based CBT compared with treatment as usual in refractory irritable bowel syndrome:the ACTIB three-arm RCT[J].Health Technol Assess,2019,23(17):1-154.DOI:10.3310/hta23170. [38]UDO I,GASH A.Management of refractory irritable bowel syndrome and comorbid mental ill-health:challenges,reflections and patient's perspective of life on the body-mind divide [J].BMJ Case Rep,2013:bcr2013009545.DOI:10.1136/bcr-2013-009545. [39]游乐卿,贾林,刘静,等.小剂量阿米替林治疗84例难治性腹泻型肠易激综合征的时-效关系及长期疗效的资料分析[J].中华行为医学与脑科学杂志,2014(12):1105-1107. [40]SONG K H,JUNG H K,KIM H J,et al.Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea,2017 Revised Edition [J].J Neurogastroenterol Motil,2018,24(2):197-215.DOI:10.5056/jnm17145. [41]WANG Y T,KWOK K F,TAN S M,et al.Comprehensive psychological intervention to improve outcome in functional gastrointestinal disorder:a cohort study[J].Singapore Med J,2015,56(7):385-392.DOI:10.11622/smedj.2015109. [42]MOSER G,TR?GNER S,GAJOWNICZEK E E,et al.Long-term success of GUT-directed group hypnosis for patients with refractory irritable bowel syndrome:a randomized controlled trial [J].Am J Gastroenterol,2013,108(4):602-609.DOI:10.1038/ajg.2013.19. [43]FLIK C E,LAAN W,ZUITHOFF N P A,et al.Efficacy of individual and group hypnotherapy in irritable bowel syndrome (IMAGINE):a multicentre randomised controlled trial[J].Lancet Gastroenterol Hepatol,2019,4(1):20-31.DOI:10.1016/s2468-1253(18)30310-8. [44]SPILLER R,AZIZ Q,CREED F,et al.Guidelines on the irritable bowel syndrome:mechanisms and practical management[J].Gut,2007,56(12):1770-1798.DOI:10.1136/gut.2007.119446. [45]李宁,田宏亮,陈启仪,等.菌群移植治疗肠道疾病2010例疗效分析 [J].中华胃肠外科杂志,2019,22(9):861-868. LI N,TIAN H L,CHEN Q Y,et al.Efficacy analysis of fecal microbiota transplantation in the treatment of 2010 patients with intestinal disorders [J].Chinese Journal of Gastrointestinal Surgery,2019,22(9):861-868. [46]DOBBIN A,DOBBIN J,ROSS S C,et al.Randomised controlled trial of brief intervention with biofeedback and hypnotherapy in patients with refractory irritable bowel syndrome[J].J R Coll Physicians Edinb,2013,43(1):15-23.DOI:10.4997/jrcpe.2013.104. [47]LAM J Y,KIDANE B,MANJI F,et al.Improved health-related quality of life after surgical management of severe refractory constipation-dominant irritable bowel syndrome[J].Int Surg,2015,100(1):63-69.DOI:10.9738/intsurg-d-13-00212.1. [48]ATTALI T V,BOUCHOUCHA M,BENAMOUZIG R.Treatment of refractory irritable bowel syndrome with visceral osteopathy:short-term and long-term results of a randomized trial[J].J Dig Dis,2013,14(12):654-661.DOI:10.1111/1751-2980.12098. [49]ZOMORODI S,ABDI S,TABATABAEE S K.Comparison of long-term effects of cognitive-behavioral therapy versus mindfulness-based therapy on reduction of symptoms among patients suffering from irritable bowel syndrome[J].Gastroenterol Hepatol Bed Bench,2014,7(2):118-124. [50]MEARIN F,CIRIZA C,MíNGUEZ M,et al.Clinical Practice Guideline:irritable bowel syndrome with constipation and functional constipation in the adult[J].Rev Esp Enferm Dig,2016,108(6):332-363.DOI:10.17235/reed.2016.4389/2016. [51]BERENS S,STROE-KUNOLD E,KRAUS F,et al.Pilot-RCT of an integrative group therapy for patients with refractory irritable bowel syndrome (ISRCTN02977330) [J].J Psychosom Res,2018,105:72-79.DOI:10.1016/j.jpsychores.2017.12.002. [52]CHEN M,TANG T C,WANG Y,et al.Randomised clinical trial:Tong-Xie-Yao-Fang granules versus placebo for patients with diarrhoea-predominant irritable bowel syndrome[J].Aliment Pharmacol Ther,2018,48(2):160-168.DOI:10.1111/apt.14817. [53]MANHEIMER E,WIELAND L S,CHENG K,et al.Acupuncture for irritable bowel syndrome:systematic review and meta-analysis[J].Am J Gastroenterol,2012,107(6):835-848.DOI:10.1038/ajg.2012.66. |
[1] | LI Qianqian, CHEN Xunrui, ZHANG Wenying, YUAN Haihua, ZHANG Yanjie, JIANG Bin, LIU Feng. Demand and Influencing Factors for Community Health Services during Chemotherapy of Patients with Advanced Cancer [J]. Chinese General Practice, 2023, 26(33): 4173-4180. |
[2] | WANG Xu, WEI Xu, ZHU Liguo, FENG Tianxiao, WANG Zhipeng, SHI Bin. Research Ideas of the Efficacy Mechanism and Prospect Analysis of Traditional Chinese Manipulative Therapy on Treating Spinal Degenerative Diseases with Combination of Medicine and Industry [J]. Chinese General Practice, 2023, 26(33): 4118-4124. |
[3] | ZHOU Yuyu, GAO Chuan, CUI Puan, WANG Yaping, HE Zhong. Influencing Factors of Shared Decision Making between Doctors and Patients in Menopausal Hormone Therapy in Patients with Menopausal Syndrome [J]. Chinese General Practice, 2023, 26(33): 4181-4186. |
[4] | SU Kaiqi, LYU Zhuan, WU Mingli, LUO Meng, GAO Jing, NIE Chenchen, LIU Hao, FENG Xiaodong. Effect of Electroacupuncture on BDNF/TrkB/PI3K/Akt Pathway and Hippocampal Neuronal Protection in Rats with Learning and Memory Impairment after Ischemia Reperfusion [J]. Chinese General Practice, 2023, 26(33): 4187-4193. |
[5] | HONG Yuchun, WU Hua, DU Yishan, LI Shuran, SUN Wenmin, YE Mingyu, ZHANG Yongjian, LI Yang. Development of General Practice Diagnostic Terminology and Coding and Empirical Study on Its Application [J]. Chinese General Practice, 2023, 26(31): 3896-3901. |
[6] | YAN Ke, WEI Wanyi, LI Shuguang, YAO Weinan, DONG Jing, WANG Xiaobin, ZHANG Xueyuan, YANG Jie, SHEN Wenbin, ZHU Shuchai. Effect of Consolidation Chemotherapy on Prognosis of StageⅡ-Ⅲ Esophageal Squamous Cell Carcinoma Patients Treated with Definitive Concurrent Chemotherapy and Radio-therapy [J]. Chinese General Practice, 2023, 26(30): 3772-3779. |
[7] | YAN Ke, WEI Wanyi, DENG Wenzhao, SHEN Wenbin, LI Shuguang, DU Xingyu, ZHANG Xueyuan, YANG Jie, ZHU Shuchai. Long-term Prognosis Analysis and Influencing Factors of Concurrent Chemotherapy and Radio-therapy for Cervical and Upper Thoracic Esophageal Squamous Cell Carcinoma [J]. Chinese General Practice, 2023, 26(30): 3785-3790. |
[8] | ZHANG Ming, XU Jing, SUN Zhenhua, ZHAO Wenhao, MA Yingqian, ZHANG Jianqiao, SHEN Haiping. Improvement of Nutritional Status of Elderly Patients with Severe Obstruction Esophageal Carcinoma by Image-guided Photodynamic Therapy [J]. Chinese General Practice, 2023, 26(30): 3780-3784. |
[9] | PU Yu, ZHANG Jixiang, DONG Weiguo. Advances in Ferroptosis and Inflammatory Bowel Disease [J]. Chinese General Practice, 2023, 26(29): 3698-3703. |
[10] | WANG Qianqian, WANG Xiaohang, ZHOU Xiaoying, QIU Shanhu, SUN Zilin. Exercise is the Foundation of Weight Loss [J]. Chinese General Practice, 2023, 26(28): 3471-3476. |
[11] | CHEN Jing, ZOU Tao, ZHAO Danqing, XIAO Ziwen, WU Xianqing, Chinese Medical Association Psychosomatic Medicine Branch Perinatal Mental Disorders Collaborative Group. Expert Consensus on Screening, Diagnosis and Treatment of Perinatal Mental Disorders [J]. Chinese General Practice, 2023, 26(28): 3463-3470. |
[12] | SUN Xiaolei, LEI Xiaolong, LIN Jiasheng, LI Keliang, GUO Ao, ZHANG Xiaohui. Effect of High Intensity Laser Combined with Physiotherapy Scoliosis Specific Exercise Therapy on Ultrasound Morphology of Multifidus Muscles in Idiopathic Scoliosis Patients with Low Back Pain [J]. Chinese General Practice, 2023, 26(27): 3456-3462. |
[13] | PEI Bei, CHENG Lin, XU Lingyun. Effects of Different Neoadjuvant Chemotherapy Regimens on Immune Indicators and Tumor Microenvironment in HER-2-positive Breast Cancer Patients [J]. Chinese General Practice, 2023, 26(27): 3435-3440. |
[14] | LIANG Xuemei, WANG Rui, ZHAO Yuhuan, XU Tianjiao, WANG Wei, SUN Weidong. Transcranial Low-level Laser Therapy: a Novel Treatment for Depression [J]. Chinese General Practice, 2023, 26(27): 3335-3341. |
[15] | CHEN Xiaofen, CHEN Yuhan, MA Juan. Recent Strides in Novel Treatments for Inflammatory Bowel Disease [J]. Chinese General Practice, 2023, 26(27): 3349-3354. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||